249 related articles for article (PubMed ID: 22537934)
21. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.
Yan M; Rayoo M; Takano EA; ; Fox SB
Breast Cancer Res Treat; 2011 Apr; 126(2):395-405. PubMed ID: 20490651
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
23. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H; van Beers E; Velds A; Liu X; Joosse SA; Klarenbeek S; Schut E; Kerkhoven R; Klijn CN; Wessels LF; Nederlof PM; Jonkers J
BMC Cancer; 2010 Aug; 10():455. PubMed ID: 20735817
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Fernández-Ramires R; Gómez G; Muñoz-Repeto I; de Cecco L; Llort G; Cazorla A; Blanco I; Gariboldi M; Pierotti MA; Benítez J; Osorio A
Int J Cancer; 2011 Jun; 128(11):2635-44. PubMed ID: 20715112
[TBL] [Abstract][Full Text] [Related]
25. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB
Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979
[TBL] [Abstract][Full Text] [Related]
26. PML protein expression in hereditary and sporadic breast cancer.
Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z
Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314
[TBL] [Abstract][Full Text] [Related]
27. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
28. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Chappuis PO; Donato E; Goffin JR; Wong N; Bégin LR; Kapusta LR; Brunet JS; Porter P; Foulkes WD
Ann Oncol; 2005 May; 16(5):735-42. PubMed ID: 15802279
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
[TBL] [Abstract][Full Text] [Related]
30. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
31. Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Lee HB; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
Breast Cancer Res Treat; 2019 May; 175(1):117-127. PubMed ID: 30671767
[TBL] [Abstract][Full Text] [Related]
32.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
33. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
34. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
[TBL] [Abstract][Full Text] [Related]
35. BRCA2 carriers with male breast cancer show elevated tumour methylation.
Deb S; Gorringe KL; Pang JB; Byrne DJ; Takano EA; ; Dobrovic A; Fox SB
BMC Cancer; 2017 Sep; 17(1):641. PubMed ID: 28893223
[TBL] [Abstract][Full Text] [Related]
36. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
37. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA; Jonasson JG; Johannsson OT; Olafsdottir K; Steinarsdottir M; Valgeirsdottir S; Eyfjord JE
Breast Cancer Res; 2009; 11(4):R47. PubMed ID: 19589159
[TBL] [Abstract][Full Text] [Related]
38. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer.
Akbari V; Kallhor M; Akbari MT
J Cell Biochem; 2019 Jan; 120(1):575-583. PubMed ID: 30125992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
